New Drug Slows Kidney Disease for 674M Patients Worldwide

Millions of people with failing kidneys just got their first real breakthrough in years.

A new study published in the New England Journal of Medicine shows that finerenone, a drug already helping diabetic kidney patients, can slow disease progression in the roughly 340 million people with chronic kidney disease who don't have diabetes. Until now, this group has had few treatment options beyond blood pressure management.

The results are striking. Researchers at University Medical Center Groningen followed 1,584 adults with kidney disease for over three years. Everyone stayed on their standard medications, but half also received finerenone.

The drug group saw kidney complications drop to 13.9%, compared to 16.9% in patients taking a placebo. That's a 23% reduction in risk of serious problems like kidney failure, heart complications, and premature death.

Clinical pharmacologist Hiddo Lambers Heerspink, who led the study, found something even more encouraging in the protein levels. After just six months, average protein in the urine had dropped by more than 41% in the finerenone group, compared with only 9% in the placebo group. High urinary protein signals ongoing kidney damage, so this steep decline suggests the drug is genuinely protecting the organs.

The timing matters because chronic kidney disease often progresses silently. Many people don't notice symptoms until their kidneys are already significantly damaged, when risks of hospitalization and death climb sharply.

The Ripple Effect

This discovery could reshape care for more than half of all kidney disease patients worldwide. Finerenone won't replace existing treatments but rather adds another layer of protection on top of standard medications that manage blood pressure and protect kidney function.

The study also confirmed the drug's safety profile in non-diabetic patients, which strengthens the case for broader use. Doctors now have a new tool to offer patients who previously faced limited options and a steady decline in kidney function.

"Finerenone could become an important new treatment option for people with chronic kidney disease who do not have diabetes," Lambers Heerspink said. "The drug offers a clear delay in the decline of kidney function on top of current standard care."

For the 674 million adults living with chronic kidney disease, this research brings something that's been in short supply: hope that progression isn't inevitable.